Format

Send to

Choose Destination

See 1 citation found by title matching your search:

Hepatogastroenterology. 2013 May;60(123):628-32.

The assessment of clinicopathological features, therapy pattern and survival benefit of 162 gastric cancers with liver metastases.

Author information

1
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education of China), Department of GI Oncology, Peking University Cancer Hospital and Institute, Beijing, China.

Abstract

BACKGROUND/AIMS:

This study investigated the influence of clinicopathological characteristics and different therapy patterns on overall survival of gastric cancer patients with liver metastases.

METHODOLOGY:

One hundred and sixty two patients were enrolled in this study. The data of clinicopathological characteristics, treatment methods and overall survival were collected. Univariate and multivariate analyses were performed using log-rank tests and Cox’s proportional hazard model, respectively.

RESULTS:

Of all the patients enrolled, 27 (16.7%) had liver-only metastases and 48 patients (28.7%) received local treatment for liver metastases. The median overall survival of the 162 patients was 9.5 months (95%CI: 8.4-10.6). One- and two-year survival rates were 28.4% and 4.3%, respectively. There was no difference in the overall survival of patients who had received the different chemotherapy regimens. Multivariate analysis revealed that numbers of liver metastases 1-3, without extrahepatic metastases, receiving local treatment for liver metastases were better prognostic factors, and HR were 0.490, 0.479, 0.495.

CONCLUSIONS:

A smaller number of liver metastases, without extrahepatic metastases and local therapy for liver metastases are the independent survival factors for gastric cancer with liver metastases.

PMID:
23108083
DOI:
10.5754/hge12729
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center